[go: up one dir, main page]

HN1997000067A - Acidos oxibutiricos sustituidos como inhibidores de la metaloproteasa de matriz - Google Patents

Acidos oxibutiricos sustituidos como inhibidores de la metaloproteasa de matriz

Info

Publication number
HN1997000067A
HN1997000067A HN1997000067A HN1997000067A HN1997000067A HN 1997000067 A HN1997000067 A HN 1997000067A HN 1997000067 A HN1997000067 A HN 1997000067A HN 1997000067 A HN1997000067 A HN 1997000067A HN 1997000067 A HN1997000067 A HN 1997000067A
Authority
HN
Honduras
Prior art keywords
compounds
disease
conditions
pharmaceutical compositions
treating
Prior art date
Application number
HN1997000067A
Other languages
English (en)
Inventor
Michael C Vanzandt
David R Brittelli
Brian R Dixon
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of HN1997000067A publication Critical patent/HN1997000067A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/38—Unsaturated compounds containing keto groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuestos que inhiben metaloproteasas de matriz , se presentan composiciones farmacéuticas de los mismos y un método de tratamiento de la enfermedad utilizando tales compuestos . Los compuestos de la invención tienen las fórmulas generales : en la que r es 0-2 , T se selecciona de y R40 es un grupo mono - o bi- heterocíclico estructura . Estos compuestos son útiles para inhibir metaloproteasas de matriz y , por lo tanto , la lucha contra las condiciones a las que contribuyen las MMP , tales como la osteoartritis , la artritis reumatoide , artritis séptica , enfermedad periodontal , ulceración corneal , proteinuria , enfermedad de aneurisma aórtico , epidermólisis distrófica , ampollosa , condiciones que conducen a inflamatoria respuestas , osteopenias mediadas por actividad de MMP, enfermedad mandibularjoint , enfermedades desmielinantes del sistema nervioso , la metástasis tumoral o pérdida degenerativa de cartílago tras lesión articular traumática , y la trombosis coronaria a partir de la ruptura de placa athrosclerotic . La presente invención también proporciona composiciones farmacéuticas y métodos para tratar tales condiciones .
HN1997000067A 1997-05-15 1997-05-16 Acidos oxibutiricos sustituidos como inhibidores de la metaloproteasa de matriz HN1997000067A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/856,693 US5925637A (en) 1997-05-15 1997-05-15 Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids

Publications (1)

Publication Number Publication Date
HN1997000067A true HN1997000067A (es) 1997-06-18

Family

ID=25324270

Family Applications (1)

Application Number Title Priority Date Filing Date
HN1997000067A HN1997000067A (es) 1997-05-15 1997-05-16 Acidos oxibutiricos sustituidos como inhibidores de la metaloproteasa de matriz

Country Status (2)

Country Link
US (6) US5925637A (es)
HN (1) HN1997000067A (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925637A (en) * 1997-05-15 1999-07-20 Bayer Corporation Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
WO2003001983A2 (en) * 2001-06-28 2003-01-09 Mount Sinai School Of Medicine Of New York University Methods for diagnosing and treating a disease mediated by decreased mmp-2 function
AU2002368151A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Matrix metalloproteinase inhibitors and methods for identification of lead compounds
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
US8088737B2 (en) 2003-04-04 2012-01-03 Incyte Corporation Compositions, methods and kits relating to Her-2 cleavage
HUE026904T2 (en) 2003-04-24 2016-08-29 Incyte Holdings Corp Aza-spiroalkane derivatives as inhibitors of metalloproteases
US7512808B2 (en) * 2003-08-29 2009-03-31 Trend Micro, Inc. Anti-computer viral agent suitable for innoculation of computing devices
BRPI0415500A (pt) 2003-10-17 2007-04-10 Incyte Corp hidroxamatos cìclicos substituìdos como inibidores de metaloproteinases de matriz
WO2005117882A2 (en) * 2004-04-20 2005-12-15 Incyte Corporation Hydroxamic acid derivatives as metalloprotease inhibitors
US20090226552A1 (en) * 2004-07-22 2009-09-10 Colorado State University Research Foundation Agents and methods for diagnosing osteoarthritis
GB0505756D0 (en) * 2005-03-21 2005-04-27 Mars Uk Ltd Method
WO2007143600A2 (en) * 2006-06-05 2007-12-13 Incyte Corporation Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
KR100959438B1 (ko) * 2007-11-30 2010-05-25 주식회사 동부하이텍 정전기방전 보호소자 및 그 제조방법
EP2310015A4 (en) * 2008-07-14 2011-10-26 Cropsolution Inc ACETYL-COENZYME-CARBOXYLASE MODULATORS AND METHODS OF USE THEREOF
CA2676946A1 (en) 2009-08-28 2011-02-28 Lucie Peduto Adam12 inhibitors and their use against inflammation-induced fibrosis
US8889638B2 (en) 2010-06-22 2014-11-18 The Regents Of The University Of California Stimulus-triggered prodrugs
GB201302755D0 (en) 2013-02-15 2013-04-03 Mars Inc Horse supplement
EP3410849B1 (en) 2016-02-05 2023-07-05 Institut Pasteur Use of inhibitors of adam12 as adjuvants in tumor therapies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3827324B2 (ja) * 1994-01-22 2006-09-27 ブリテッシュ バイオテック ファーマシューティカルズ リミテッド 金属タンパク質分解酵素阻害剤
US5789434A (en) 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
US5925637A (en) * 1997-05-15 1999-07-20 Bayer Corporation Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids
MY132463A (en) * 1996-05-15 2007-10-31 Bayer Corp Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids

Also Published As

Publication number Publication date
US6500847B2 (en) 2002-12-31
US20020042417A1 (en) 2002-04-11
US20050267102A1 (en) 2005-12-01
US6911449B2 (en) 2005-06-28
US20020042418A1 (en) 2002-04-11
US6762184B2 (en) 2004-07-13
US20040127500A1 (en) 2004-07-01
US5925637A (en) 1999-07-20
US6225314B1 (en) 2001-05-01

Similar Documents

Publication Publication Date Title
HN1997000067A (es) Acidos oxibutiricos sustituidos como inhibidores de la metaloproteasa de matriz
AR007098A1 (es) Inhibidores de la metaloproteasa de matriz, composiciones que los comprenden, y uso de los mismos para preparar composiciones farmaceuticas
AR001999A1 (es) Derivados de acido carboxilico y composiciones conteniendolos, utiles como inhibidores de metaloproteasa de matriz, y procesos para su preparacion.
CO4700432A1 (es) Derivados del acido arilsulfonilamino hidroxalico
ES2136037B1 (es) Inhibidores de sulfamida-metaloproteasa
UY27154A1 (es) Pirimidinas inhibidoras de metaloproteinasa de matriz
PT971888E (pt) Compostos de 2-alquil-19-nor-vitamina d
AR004672A1 (es) Derivados de la banzo(g)quinolina, proceso para prepararlos,su utilizacion como productos farmaceuticos, las composiciones farmaceuticas que los contieneny los metodos de tratamiento de la depresion, ansiedad y desordenes bipolares que utilizan dichos compuestos.
PA8456801A1 (es) Derivados de acidos ariloxiarilsulfonilamino hidroxamicos
BR0007759A (pt) Composto, processo para preparar o mesmo,composição farmacêutica, e, métodos para tratarcondições de doença mediadas pelametaloproteinase de matriz em um mamìfero emnecessidade deste, e para tratar um paciente quesofre de uma condição selecionada do grupo queconsiste de osteoartrite, artrite reumatóide,perda de cartilagem degenerativa edesenvolvimento de tumor
ATE232873T1 (de) Phosphonsaürederivate als ptp-1b-inhibitoren
MX2024009447A (es) Inhibidores de proteina tirosina fosfatasa y usos de estos
YU18397A (en) MATRIX METALLOPROTEASES INHIBITING COMPOUND, 2(ω-ARYOYL-ALKYL)-4-BIARYL-4-OXOBUTYRIC ACID
AR007100A1 (es) Inhibicion de las metaloproteasas de matriz por compuestos de fenilalquilo sustituido y el uso de los mismos para la preparacion de un medicamento.
YU18697A (en) Biaryl acetilenes as inhibitors of matrix metalloproteases
ECSP972113A (es) Inhibicion de las metaloproteasas de matriz por acidos biariloxobutiricos sustituidos
HN2001000011A (es) Eteres de dicarboxilato de calcio, metodos para su preparacion y tratamiento de las enfermedades vasculares y diabetes con los mismos.
ECSP972112A (es) Inhibicion de las metaloproteasas de matriz por compuestos de fenetilo sustituido
ECSP972114A (es) Biarilacetilenos como inhibidores de la metaloproteasa de matriz
BR9910095A (pt) Compostos inibidores de spla2 para tratamento de doença
ECSP972115A (es) Acidos oxibutiricos sustituidos como inhibidores de la metaloproteasa de matriz
ECSP972111A (es) Inhibidores de la metaloproteinasas de matriz por acidos 2-(aroilalquil)-4 biaril-4- oxobutiricos
DE69918826D1 (de) Arylnitron therapeutische mittel zur behandlung von entzündlichen darmerkrankungen
BR0308088A (pt) ácidos alfa-iminocarboxìlicos substituìdos com n, cìclicos, para a inibição seletiva de colagenase
ECSP961719A (es) Derivados del acido aril sulfonil hidroxamico